Jennifer Lynn Guerriero, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tumor Microenvironment | 17 | 2024 | 3508 | 1.140 |
Why?
|
Macrophages | 8 | 2024 | 5631 | 1.130 |
Why?
|
Receptors, Progesterone | 3 | 2021 | 1094 | 0.720 |
Why?
|
Neovascularization, Pathologic | 2 | 2021 | 2639 | 0.680 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2021 | 522 | 0.650 |
Why?
|
Breast Neoplasms | 10 | 2024 | 20676 | 0.620 |
Why?
|
Neoplasms, Experimental | 3 | 2020 | 1280 | 0.610 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2021 | 788 | 0.540 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2011 | 628 | 0.530 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2370 | 0.510 |
Why?
|
Receptors, Estrogen | 3 | 2024 | 2183 | 0.500 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2021 | 1029 | 0.500 |
Why?
|
Immunotherapy | 7 | 2024 | 4391 | 0.420 |
Why?
|
Immune Tolerance | 1 | 2021 | 2256 | 0.420 |
Why?
|
Cell Line, Tumor | 15 | 2024 | 16646 | 0.390 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2021 | 5148 | 0.370 |
Why?
|
HMGB1 Protein | 1 | 2011 | 131 | 0.350 |
Why?
|
Glioblastoma | 1 | 2023 | 3431 | 0.320 |
Why?
|
Myeloid Cells | 2 | 2023 | 799 | 0.300 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5522 | 0.300 |
Why?
|
Apoptosis | 8 | 2021 | 9714 | 0.300 |
Why?
|
Neoplasms | 6 | 2023 | 21507 | 0.290 |
Why?
|
Lung Neoplasms | 2 | 2024 | 12985 | 0.280 |
Why?
|
Immunity, Innate | 3 | 2019 | 2950 | 0.280 |
Why?
|
bcl-X Protein | 2 | 2019 | 413 | 0.270 |
Why?
|
T-Lymphocytes | 2 | 2021 | 10142 | 0.250 |
Why?
|
Cyclophosphamide | 1 | 2008 | 2238 | 0.220 |
Why?
|
Phagocytosis | 2 | 2018 | 1539 | 0.200 |
Why?
|
Antineoplastic Agents | 4 | 2019 | 13635 | 0.200 |
Why?
|
Transplantation, Isogeneic | 1 | 2021 | 257 | 0.200 |
Why?
|
Antibodies, Bispecific | 1 | 2023 | 164 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 11410 | 0.190 |
Why?
|
Furans | 1 | 2021 | 186 | 0.190 |
Why?
|
Ketones | 1 | 2021 | 182 | 0.190 |
Why?
|
Professional-Family Relations | 2 | 2021 | 481 | 0.180 |
Why?
|
Allergy and Immunology | 1 | 2021 | 169 | 0.180 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2023 | 482 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2023 | 4424 | 0.180 |
Why?
|
Death Domain Receptor Signaling Adaptor Proteins | 1 | 2019 | 34 | 0.170 |
Why?
|
Mammary Glands, Animal | 1 | 2020 | 276 | 0.170 |
Why?
|
Mice | 14 | 2024 | 81002 | 0.170 |
Why?
|
Caregivers | 2 | 2021 | 2067 | 0.170 |
Why?
|
Neoplasm Transplantation | 2 | 2021 | 2084 | 0.160 |
Why?
|
Animals | 18 | 2024 | 168368 | 0.160 |
Why?
|
Pyrimidinones | 1 | 2020 | 371 | 0.160 |
Why?
|
Health Communication | 1 | 2021 | 212 | 0.160 |
Why?
|
Seizures | 2 | 2021 | 2829 | 0.160 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 171 | 0.160 |
Why?
|
Macrophage Activation | 2 | 2020 | 558 | 0.160 |
Why?
|
Cisplatin | 2 | 2020 | 1617 | 0.150 |
Why?
|
Humans | 43 | 2024 | 739398 | 0.150 |
Why?
|
Receptors, Immunologic | 1 | 2024 | 1424 | 0.150 |
Why?
|
Oxadiazoles | 1 | 2017 | 92 | 0.150 |
Why?
|
Parents | 2 | 2021 | 3368 | 0.150 |
Why?
|
Necrosis | 3 | 2011 | 1643 | 0.150 |
Why?
|
BRCA1 Protein | 2 | 2020 | 1143 | 0.140 |
Why?
|
Urothelium | 1 | 2019 | 277 | 0.140 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2020 | 3562 | 0.140 |
Why?
|
Drug Synergism | 2 | 2017 | 1792 | 0.140 |
Why?
|
Infant, Newborn, Diseases | 1 | 2021 | 578 | 0.140 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2019 | 1157 | 0.130 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4832 | 0.130 |
Why?
|
Paclitaxel | 5 | 2023 | 1701 | 0.130 |
Why?
|
Neoadjuvant Therapy | 3 | 2023 | 2688 | 0.130 |
Why?
|
Stromal Cells | 1 | 2020 | 1350 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 575 | 0.130 |
Why?
|
Immunologic Factors | 2 | 2021 | 1571 | 0.130 |
Why?
|
Mice, Nude | 3 | 2011 | 3692 | 0.120 |
Why?
|
Adaptive Immunity | 1 | 2019 | 709 | 0.120 |
Why?
|
Hydroxamic Acids | 1 | 2017 | 495 | 0.120 |
Why?
|
Female | 23 | 2024 | 378853 | 0.120 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9387 | 0.120 |
Why?
|
Antigens, CD | 1 | 2023 | 4024 | 0.110 |
Why?
|
Drug Administration Schedule | 1 | 2021 | 4935 | 0.110 |
Why?
|
Membrane Glycoproteins | 1 | 2024 | 3768 | 0.110 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4815 | 0.110 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2023 | 1607 | 0.100 |
Why?
|
Multiple Myeloma | 3 | 2020 | 5147 | 0.100 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 480 | 0.100 |
Why?
|
Colorectal Neoplasms | 2 | 2022 | 6726 | 0.100 |
Why?
|
Benzamides | 1 | 2017 | 1374 | 0.100 |
Why?
|
Tumor Burden | 1 | 2017 | 1904 | 0.100 |
Why?
|
Cell Proliferation | 4 | 2021 | 10455 | 0.090 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2010 | 75 | 0.090 |
Why?
|
Pyrazoles | 1 | 2020 | 1963 | 0.090 |
Why?
|
Cell Differentiation | 2 | 2018 | 11460 | 0.090 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2727 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2936 | 0.090 |
Why?
|
Cell Line, Transformed | 1 | 2011 | 897 | 0.090 |
Why?
|
Adaptation, Psychological | 1 | 2020 | 2564 | 0.090 |
Why?
|
Serpins | 1 | 2011 | 248 | 0.090 |
Why?
|
Adenovirus E1A Proteins | 1 | 2008 | 76 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3606 | 0.080 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9734 | 0.080 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2008 | 75 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2020 | 3671 | 0.080 |
Why?
|
Peptides | 2 | 2024 | 4395 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1431 | 0.080 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2530 | 0.080 |
Why?
|
Fibroblasts | 2 | 2016 | 4137 | 0.080 |
Why?
|
Genome, Human | 2 | 2021 | 4419 | 0.080 |
Why?
|
bcl-2-Associated X Protein | 1 | 2008 | 293 | 0.080 |
Why?
|
Cytokines | 2 | 2021 | 7298 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2019 | 2196 | 0.070 |
Why?
|
Random Allocation | 1 | 2011 | 2417 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 3101 | 0.070 |
Why?
|
Biomedical Research | 1 | 2021 | 3301 | 0.070 |
Why?
|
Genes, ras | 1 | 2008 | 693 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5213 | 0.060 |
Why?
|
Lung | 1 | 2024 | 9782 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2021 | 9622 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 7897 | 0.060 |
Why?
|
Pyrimidines | 1 | 2017 | 2918 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2020 | 4212 | 0.060 |
Why?
|
Taxoids | 1 | 2008 | 661 | 0.060 |
Why?
|
Signal Transduction | 3 | 2021 | 23355 | 0.060 |
Why?
|
HEK293 Cells | 2 | 2011 | 4174 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2021 | 4189 | 0.060 |
Why?
|
Genomics | 4 | 2021 | 5652 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 8400 | 0.060 |
Why?
|
DNA, Neoplasm | 1 | 2008 | 1754 | 0.060 |
Why?
|
Physicians | 1 | 2021 | 4539 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2011 | 1977 | 0.060 |
Why?
|
Cells, Cultured | 3 | 2020 | 19220 | 0.060 |
Why?
|
Autophagy | 1 | 2010 | 1295 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 12049 | 0.050 |
Why?
|
Qualitative Research | 2 | 2021 | 2656 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7862 | 0.050 |
Why?
|
Aging | 1 | 2020 | 8613 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2021 | 62693 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9259 | 0.050 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 2141 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2017 | 18003 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 23294 | 0.040 |
Why?
|
Time Factors | 1 | 2021 | 40050 | 0.040 |
Why?
|
Nuclear Family | 1 | 2020 | 318 | 0.040 |
Why?
|
Nucleotides, Cyclic | 1 | 2019 | 81 | 0.040 |
Why?
|
Atlases as Topic | 1 | 2020 | 235 | 0.040 |
Why?
|
Male | 12 | 2023 | 349022 | 0.040 |
Why?
|
DNA Damage | 1 | 2008 | 2419 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5154 | 0.040 |
Why?
|
Prospective Studies | 5 | 2023 | 53037 | 0.040 |
Why?
|
Prognosis | 4 | 2021 | 28901 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 727 | 0.040 |
Why?
|
Disease Progression | 4 | 2019 | 13237 | 0.040 |
Why?
|
Object Attachment | 1 | 2020 | 312 | 0.040 |
Why?
|
Risk Factors | 2 | 2022 | 71974 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2020 | 673 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 301 | 0.040 |
Why?
|
Burns | 1 | 2008 | 1808 | 0.040 |
Why?
|
Carboplatin | 1 | 2019 | 800 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1096 | 0.030 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 222 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2021 | 1286 | 0.030 |
Why?
|
Uncertainty | 1 | 2020 | 721 | 0.030 |
Why?
|
Cytochromes c | 1 | 2015 | 180 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 678 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1561 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2019 | 788 | 0.030 |
Why?
|
Parenting | 1 | 2020 | 672 | 0.030 |
Why?
|
Teratoma | 1 | 2016 | 386 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2021 | 2448 | 0.030 |
Why?
|
Middle Aged | 7 | 2023 | 212863 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1199 | 0.030 |
Why?
|
Phenotype | 2 | 2021 | 16301 | 0.030 |
Why?
|
Aged | 6 | 2023 | 162698 | 0.030 |
Why?
|
Mitochondria | 2 | 2016 | 3522 | 0.030 |
Why?
|
Lymphocytes | 1 | 2020 | 2612 | 0.030 |
Why?
|
Transcription Factors | 2 | 2023 | 12120 | 0.030 |
Why?
|
Mutation | 3 | 2024 | 29658 | 0.030 |
Why?
|
Histone Deacetylases | 1 | 2017 | 729 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3453 | 0.030 |
Why?
|
Biological Assay | 1 | 2015 | 653 | 0.030 |
Why?
|
Leadership | 1 | 2021 | 1349 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 1994 | 0.030 |
Why?
|
Plasma Cells | 1 | 2015 | 591 | 0.030 |
Why?
|
Fear | 1 | 2020 | 1430 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2455 | 0.020 |
Why?
|
Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 18 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 25470 | 0.020 |
Why?
|
Aniline Compounds | 1 | 2015 | 990 | 0.020 |
Why?
|
Testicular Neoplasms | 1 | 2016 | 758 | 0.020 |
Why?
|
Organ Specificity | 1 | 2015 | 2004 | 0.020 |
Why?
|
Phosphatidylinositol Phosphates | 1 | 2010 | 209 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2011 | 287 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2020 | 2728 | 0.020 |
Why?
|
Phagosomes | 1 | 2010 | 194 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2789 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2011 | 552 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1674 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2020 | 3433 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2010 | 314 | 0.020 |
Why?
|
Patient Care Team | 1 | 2020 | 2527 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5830 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3571 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1936 | 0.020 |
Why?
|
Biopolymers | 1 | 2008 | 183 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8605 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12761 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3051 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2019 | 4374 | 0.020 |
Why?
|
Adult | 4 | 2021 | 213394 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10247 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2948 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12328 | 0.020 |
Why?
|
Sulfonamides | 1 | 2015 | 1934 | 0.020 |
Why?
|
Anxiety | 1 | 2020 | 4253 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2008 | 740 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11347 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2008 | 1801 | 0.020 |
Why?
|
Smoking | 1 | 2022 | 8960 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2010 | 1698 | 0.020 |
Why?
|
Tubulin | 1 | 2008 | 696 | 0.020 |
Why?
|
Incidence | 1 | 2022 | 20913 | 0.010 |
Why?
|
Recurrence | 1 | 2015 | 8307 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 21863 | 0.010 |
Why?
|
Point Mutation | 1 | 2008 | 1626 | 0.010 |
Why?
|
Drug Design | 1 | 2008 | 1088 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2008 | 3146 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 2507 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2010 | 3770 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2011 | 6871 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2022 | 38942 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 2381 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 3802 | 0.010 |
Why?
|
Infant | 1 | 2021 | 34923 | 0.010 |
Why?
|
Ischemia | 1 | 2008 | 1908 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 12640 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 40802 | 0.010 |
Why?
|
Heart | 1 | 2010 | 4466 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8299 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2011 | 10961 | 0.010 |
Why?
|
Biopsy | 1 | 2008 | 6722 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2010 | 14558 | 0.010 |
Why?
|
Pilot Projects | 1 | 2008 | 8275 | 0.010 |
Why?
|
Liver | 1 | 2010 | 7449 | 0.010 |
Why?
|
Skin | 1 | 2008 | 4324 | 0.010 |
Why?
|
Young Adult | 1 | 2020 | 56255 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 19811 | 0.010 |
Why?
|
United States | 1 | 2020 | 69573 | 0.010 |
Why?
|
Rats | 1 | 2008 | 24270 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 57650 | 0.010 |
Why?
|